Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase NA 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 3863Neoplasms 2988Prostatic Neoplasms 1754Colorectal Neoplasms 1430Lung Neoplasms 1331Motor Activity 805Head and Neck Neoplasms 686Pancreatic Neoplasms 663Colonic Neoplasms 655Uterine Cervical Neoplasms 653Carcinoma, Non-Small-Cell Lung 631Carcinoma, Hepatocellular 631Rectal Neoplasms 571Stomach Neoplasms 547Brain Neoplasms 484Ovarian Neoplasms 441Anxiety Disorders 420Pain 419Neoplasm Metastasis 385Esophageal Neoplasms 384Polycystic Ovary Syndrome 374Precursor Cell Lymphoblastic Leukemia-Lymphoma 354Urinary Bladder Neoplasms 351Fatigue 340Melanoma 323Multiple Myeloma 322Lymphoma 306Depression 306Endometrial Neoplasms 290Liver Neoplasms 279

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Interventional × Hypereosinophilic Syndrome × Clear all
NCT00038675 2022-01-04

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

M.D. Anderson Cancer Center

Phase NA Completed
125 enrolled 9 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Polycythemia Vera, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡